The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines

European Journal of Biochemistry

Volumn 271, Issue 13, 2004, Pages 2773-2781

  Liu, Wai M ^a,b   Scott, Katherine A ^a,b   Shahin, Sipra ^a   Propper, David J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

cAMP response element; Colorectal cancer; Oligonucleotide decoy factors; Synergy

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 4; ETOPOSIDE; FLUOROURACIL; OLIGONUCLEOTIDE; PROTEIN P21;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ACTIVITY; CELL DEATH; CHEMOTHERAPY; CLINICAL OBSERVATION; COLORECTAL CANCER; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; CYTOSTASIS; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; PH; PRIORITY JOURNAL; PROTEIN FUNCTION; UPREGULATION;

BASE SEQUENCE; CAMPTOTHECIN; CELL DIVISION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASES; ETOPOSIDE; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; OLIGONUCLEOTIDES;

EID: 3042725531     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-1033.2004.04208.x     Document Type: Article

References (32)

1. Cho-Chung, Y.S., Park, Y.G. & Lee, Y.N. (1999) Oligonucleotides as transcription factor decoys. Curr. Opin. Mol. Ther. 1, 386-392.
2. Wang, H., Prasad, G., Buolamwini, J.K. & Zhang, R. (2001) Antisense anticancer oligonucleotide therapeutics. Curr. Cancer Drug Targets 1, 177-196.
3. Cho-Chung, Y.S. (2002) Antisense DNAs as targeted therapeutics for cancer: no longer a dream. Curr. Opin. Invest. Drugs 3, 934-939.
4. Cho-Chung, Y.S. (2003) Antisense DNAs as targeted genetic medicine to treat cancer. Arch. Pharm. Res. 26, 183-191.
5. Stephens, A.C. & Rivers, R.P. (2003) Antisense oligonucleotide therapy in cancer. Curr. Opin. Mol. Ther. 5, 118-122.
6. Bergan, R., Connell, Y., Fahmy, B., Kyle, E. & Neckers, L. (1994) Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res. 22, 2150-2154.
7. Smetsers, T.F., Linders, E.H., van de Locht, L.T., de Witte, T.M. & Mensink, E.J. (1997) An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism. Br. J. Haematol. 96, 377-381.
8. Juliano, R.L., Alahari, S., Yoo, H., Kole, R. & Cho, M. (1999) Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. Pharm. Res. 16, 494-502.
9. Juliano, R.L. & Yoo, H. (2000) Aspects of the transport and delivery of antisense oligonucleotides. Curr. Opin. Mol. Ther. 2, 297-303.
10. Gewirtz, A.M. (1999) Oligonucleotide therapeutics: clothing the emperor. Curr. Opin. Mol. Ther. 1, 297-306.
11. Jahagirdar, B.N., Miller, J.S., Shet, A. & Verfaillie, C.M. (2001) Novel therapies for chronic myelogenous leukemia. Exp. Hematol. 29, 543-556.
12. Tomita, N., Morishita, R., Tomita, T. & Ogihara, T. (2002) Potential therapeutic applications of decoy oligonucleotides. Curr. Opin. Mol. Ther. 4, 166-170.
13. Roesler, W.J., Graham, J.G., Kolen, R., Klemm, D.J. & Mcfie, P.J. (1995) The cAMP response element binding protein synergizes with other transcription factors to mediate cAMP responsiveness. J. Biol. Chem. 270, 8225-8232.
14. Shaywitz, A.J. & Greenberg, M.E. (1999) CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 68, 821-861.
15. Montminy, M.R. & Bilezikjian, L.M. (1987) Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature 328, 175-178.
16. De Cesare, D., Fimia, G.M. & Sassone-Corsi, P. (1999) Signaling routes to CREM and CREB: plasticity in transcriptional activation. Trends Biochem. Sci. 24, 281-285.
17. Park, Y.G., Nesterova, M., Agrawal, S. & Cho-Chung, Y.S. (1999) Dual blockade of cyclic AMP response element-(CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide. gene-specific inhibition of tumor growth. J. Biol. Chem. 274, 1573-1580.
18. Lee, Y.N., Park, Y.G., Choi, Y.H., Cho, Y.S. & Cho-Chung, Y.S. (2000) CRE-transcription factor decoy oligonucleotide inhibition of MCF-7 breast cancer cells: cross-talk with p53 signaling pathway. Biochemistry 39, 4863-4868.
19. Park, Y.G., Park, S., Lim, S.O., Lee, M.S., Ryu, C.K., Kim, I. & Cho-Chung, Y.S. (2001) Reduction in Cyclin D1/CDK4/Retinoblastoma Protein Signalling by CRE-Decoy Oligonucleotide. Biochem. Biophys. Res. Commun 281, 1213-1219.
20. Alper, O., Bergmann-Leitner, E.S., Abrams, S. & Cho-Chung, Y.S. (2001) Apoptosis, growth arrest and suppression of invasiveness by CRE-decoy oligonucleotide in ovarian cancer cells: protein kinase A downregulation and cytoplasmic export of CRE-binding proteins. Mol. Cell. Biochem. 218, 55-63.
21. Henry, S.P., Geary, R.S., Yu, R. & Levin, A.A. (2001) Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr. Opin. Invest. Drugs 2, 1444-1449.
22. Fisher, A.A., Ye, D., Sergueev, D.S., Fisher, M.H., Shaw, B.R. & Juliano, R.L. (2002) Evaluating the specificity of antisense oligonucleotide conjugates: a DNA array analysis. J. Biol. Chem. 277, 22980-22984.
23. Liu, W.M., Oakley, P.R. & Joel, S.P. (2002) Exposure to low concentration of etoposide reduces the apoptotic capability of leukaemic cell lines. Leukemia 16, 1705-1712.
24. te Poele, R.H., Okorokov, A.L., Jardine, L., Cummings, J. & Joel, S.P. (2002) DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 61, 1876-1883.
25. Liu, W.M., Stimson, L.A. & Joel, S.P. (2002) The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive CML cells: Synergistic interactions with anti-leukaemic agents. Br. J. Cancer 86, 1472-1478.
26. Cho, Y.S., Kim, M.K., Cheadle, C., Neary, C., Park, Y.G., Becker, K.G. & Cho-Chung, Y.S. (2002) A genomic-scale view of the cAMP response element-enhancer decoy: a tumor target-based genetic tool. Proc. Natl Acad. Sci. USA 99, 15626-15631.
27. Han, Z., Wei, W., Dunaway, S., Darnowski, J.W., Calabresi, P., Sedivy, J., Hendrickson, E.A., Balan, K.V., Pantazis, P. & Wyche, J.H. (2002) Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem. 277, 17154-17160.
28. Sherr, C.J. (1993) Mammalian G1 cyclins. Cell 73, 1059-1065.
29. Nurse, P. (1994) Ordering S phase and M phase in the cell cycle. Cell 79, 583-589.
30. El-Deiry (1998) p21/p53; cellular growth control and genomic integrity. Curr. Top. Microbiol. Immunol. 227, 121-237.
31. Mcdonald, E.R. & El-Deiry, W.S. (2000) Cell cycle control as a basis for cancer drug development. Int. J. Oncol. 16, 871-886.
32. Murray, A.W. (2004) Recycling the cell cycle: cyclins revisited. Cell 116, 221-234.